Home / Resources / Test Your Knowledge / CV Risk in Patients with Diabetes

CV Risk in Patients with Diabetes

Sep 15, 2018
 

There is an antidiabetic medication available on the US market with an indication from the US Food and Drug Administration (FDA) to prevent cardiovascular (CV) disease.

Correct

Explanation:  In December 2016, the FDA approved a new indication for Jardiance® (empagliflozin) to reduce CV risk in adult patients with type 2 diabetes (T2D) and CV disease. The decision was based on a postmarket clinical trial in which 7,000 patients with T2D and CV disease were given empagliflozin vs placebo. Empagliflozin was shown to reduce the risk for CV death compared with placebo when added to standard-of-care therapies for T2D and atherosclerotic CV disease.

Sources:

US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes.            https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Published December 2, 2016.

ADA. Diabetes Care. 2017;40(Suppl 1):S65.  Novo Nordisk. https://globenewswire.com/news-release/. 2016. Package insert for Jardiance®.

Incorrect